shareshare link cite add Please grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19

Microsoft Academic Graph classification: Hydroxychloroquine medicine.drug medicine Internal medicine medicine.medical_specialty Lopinavir business.industry business Favipiravir Lopinavir/ritonavir Coronavirus disease 2019 (COVID-19) Context (language use) Ritonavir
Medical Subject Headings: virus diseases immune system diseases
covid-19, hydroxychloroquine, favipiravir, lopinavir/ritonavir, adverse reactions, vigibase, Medicine (General), R5-920
covid-19, hydroxychloroquine, favipiravir, lopinavir/ritonavir, adverse reactions, vigibase, Medicine (General), R5-920
Microsoft Academic Graph classification: Hydroxychloroquine medicine.drug medicine Internal medicine medicine.medical_specialty Lopinavir business.industry business Favipiravir Lopinavir/ritonavir Coronavirus disease 2019 (COVID-19) Context (language use) Ritonavir
Medical Subject Headings: virus diseases immune system diseases